NCT05852340View on ClinicalTrials.gov

A Study to Assess Two Forms of The Study Medicine (Ritlecitinib) in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 9, 2023

Primary Completion Date

June 15, 2023

Study Completion Date

July 24, 2023

Conditions
Healthy VolunteersAdultPharmacokinetics
Interventions
DRUG

Ritlecitinib

"ritlecitinib 1 x 30 mg intact BiC (Treatment Arms A, E)~ritlecitinib 1 x 30 mg intact BiC sprinkled on soft foods (Treatment Arms B, C, D)"

Trial Locations (1)

B-1070

Pfizer Clinical Research Unit - Brussels, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05852340 - A Study to Assess Two Forms of The Study Medicine (Ritlecitinib) in Healthy Adult Participants | Biotech Hunter | Biotech Hunter